Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

EvoXRare-Assisted Chest Radiograph Interpretation in Emergency and Critically Ill Adults: A Nationwide Multicenter Randomized Controlled Trial

NCT07925476 is registered in ClinicalTrials.gov with Union Hospital, Tongji Medical College, Huazhong University of Science and Technology as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07925476 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
EvoXRare-Assisted Chest Radiograph Interpretation in Emergency and Critically Ill Adults: A Nationwide Multicenter Randomized Controlled Trial
Lead sponsor
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase
Phase 1
Overall status
Not yet recruiting
Start date
November 1, 2026
Completion date
November 1, 2028
Enrollment
70,000 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

chest radiography, diagnostic error, emergency and critical care, thoracic abnormalities

Arms

As registered; 2 arms.

  • EvoXRare AI-Assisted Chest Radiograph Interpretation. ExperimentalExperimental: EvoXRare AI-Assisted Chest Radiograph Interpretation.

    Usual chest radiograph interpretation plus access to EvoXRare-generated draft report and high-risk prompts. The physician reviews the original image, accepts/rejects/edits AI suggestions, submits the final report, and follows local critical-result communication procedures.

  • No Intervention / Active usual-care comparator: Standard Chest Radiograph Interpretation. No intervention

    Routine physician interpretation according to the participating hospital's usual workflow, without access to EvoXRare trial output. Routine nontrial tools already in use may continue only if documented before site activation and applied consistently.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Patient-Level Clinically Important Abnormality Miss Rate on the Index Chest Radiograph From index radiograph interpretation through completion of blinded endpoint adjudication, using clinically available information obtained during the index encounter and prespecified follow-up window (target: within 30 days when available).

    Proportion of randomized participants with at least one prespecified clinically important abnormality (Category A or B) judged present on the reference standard but absent from the initial finalized chest radiograph report produced under the assigned strategy.

Lead sponsor's other trials

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, most recent start first.

Similar trials

Same condition (Emergencies) and phase, most recent start first.